NasdaqGS:RGENLife Sciences
Is Q1 Beat And Reaffirmed 2026 Guidance Altering The Investment Case For Repligen (RGEN)?
In recent weeks, RBC Capital resumed coverage on Repligen Corporation with an Outperform rating after the company reported Q1 2026 revenue and adjusted EPS that exceeded analyst forecasts and reaffirmed its full-year 2026 guidance.
The combination of better-than-expected quarterly results and confidence in maintaining full-year targets reinforces Repligen’s efforts to accelerate profitable growth in the bioprocess market.
Next, we’ll examine how Repligen’s Q1 beat and reaffirmed guidance...